DR. GLENN LAURENCE COOPER, MD
Osteopathic Medicine at Old Connecticut Path, Wayland, MA
License number
Massachusetts 01061855A
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
196 Old Connecticut Path, Wayland, MA 01778
Phone
(617) 513-1049
(508) 358-7558 (Fax)
(508) 358-7558 (Fax)
Professional information
Dr. Glenn L Cooper, Wayland MA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
196 Old Connecticut Path, Wayland 01778
(617) 513-1049 (Phone), (508) 358-7558 (Fax)
(617) 513-1049 (Phone), (508) 358-7558 (Fax)
Certifications:
Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Tufts University
Tufts University
Treatment Of Interstitial Cystitis Using (6Ar, 10Ar)-Δ-Tetrahydrocannabinol-11-Oic Acids
US Patent:
8637087, Jan 28, 2014
Filed:
Nov 23, 2009
Appl. No.:
12/624313
Inventors:
Glenn L. Cooper - Wayland MA, US
Assignee:
JB Therapeutics Inc. - Newton Center MA
International Classification:
A61K 31/352, A61K 31/437, A61P 23/00
US Classification:
424618, 424725, 514455, 514304, 514317, 514305, 514424, 514291, 514256, 514217, 514 56, 514454
Abstract:
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.
Treatment Of Interstitial Cystitis Using (6Ar, 10Ar)-Delta-8-Tetrahydrocannabinol-11-Oic Acids
US Patent:
2008018, Jul 31, 2008
Filed:
Feb 15, 2008
Appl. No.:
12/070342
Inventors:
Bobby W. Sandage - Acton MA, US
Glenn L. Cooper - Wayland MA, US
Glenn L. Cooper - Wayland MA, US
Assignee:
Indevus Pharmaceuticals, Inc. - Lexington MA
International Classification:
A61K 31/352, A61P 13/10
US Classification:
514454
Abstract:
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.
Treatment Of Interstitial Cystitis Using (6Ar,10Ar)-Delta8-Tetrahydrocannabinol-11-Oic Acids
US Patent:
2006012, Jun 15, 2006
Filed:
Dec 13, 2005
Appl. No.:
11/299688
Inventors:
Bobby Sandage - Acton MA, US
Glenn Cooper - Wayland MA, US
Glenn Cooper - Wayland MA, US
Assignee:
Indevus Pharmaceuticals, Inc. - Lexington MA
International Classification:
A61K 31/353
US Classification:
514454000
Abstract:
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.
Treatment Of Interstitial Cystitis Using Cannabinoid Analogs
US Patent:
2006012, Jun 15, 2006
Filed:
Dec 13, 2005
Appl. No.:
11/299661
Inventors:
Bobby Sandage - Acton MA, US
Glenn Cooper - Wayland MA, US
Glenn Cooper - Wayland MA, US
Assignee:
Indevus Pharmaceuticals, Inc. - Lexington MA
International Classification:
A61K 31/473, A61K 31/353, A61K 31/192, A61K 31/19, A61K 31/22
US Classification:
514290000, 514454000, 514546000, 514568000
Abstract:
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses cannabinol analogs, which are preferably analogs of (6aR,10aR)-Δ-tetrahydrocannabinol-11-oic acids [hereinafter referred to as (6aR,10aR)-Δ-THC-11-oic acid], as well as pharmaceutical compositions containing the cannabinol analogs and analogs of (6aR,10aR)-Δ-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.